Overview

This trial is active, not recruiting.

Condition spinal stenosis
Treatment i-factor
Phase phase 3
Sponsor Sygehus Lillebaelt
Collaborator CeraPedics, Inc
Start date March 2012
End date June 2013
Trial size 108 participants
Trial identifier NCT01618435, F12-04

Summary

The average life expectancy in Denmark is increasing resulting in an increasing part of the population having age-related disease, ex lumbar spinal stenosis (LSS). LSS causes constriction of the nerves in the lumbar spine resulting in pain in the legs and lower back, especially when standing and walking, known as neurogenic claudication(Goh KJ FAU - Khalifa et al.). LSS occurs in a combination of degenerative changes in the lower back, including hypertrophy of the ligamentum flavus, arthrosis of the facet joints and bulging of the disc.

Current treatment of LSS is varied ranging from non-operative conservative treatment to operation.

Operative intervention shows very good results according to physical ability and pain(Christensen FB et al.;Hee HT and Wong;McGregor AH FAU - Hughes and Hughes;Xu et al.), but the most optimal treatment is still debated. Nevertheless, a decompression and, if needed, a spinal fusion is recommended.(Ausman).

Clinical improvement including decrease of pain, improved ADL-function and an increased quality of life are parameters of highest interest and the purpose of an operation is clear: Making sufficient room for the affected nerves. In addition fusion is desired achieving stability avoiding a new compression of the nerves. Studies attending these issues find a correlation between fusion and clinical outcome, why obtained fusion of the affected levels are very important(Andersen et al.;Andersen et al.;Girardo et al.;Kornblum MB FAU - Fischgrund et al.).

P-15, bound to Anorganisk Bone Mineral (ABM), called i-FACTOR®, shows fusion superiority, no side effects and no risk of transferring disease(Thorwarth et al. 5648-57;Thorwarth et al. 789-95;Wenz, Oesch, and Horst 1599-606;Scarano et al. 318-24;Kubler et al. 171-79) why the investigators find this material suited for fusion surgery in the elderly.

To the investigators knowledge this is the first prospective study comparing fusion rates and postoperative clinic with i-FACTOR vs allograft in older patients operated with decompression and spondylodesis because of spinal stenosis due to degenerative spondylolisthesis.

Hypothesis:

There are no difference in the clinical parameters measured by ODI and fusion rates comparing i-FACTOR® and allograft in non-instrumented posterolateral spondylodesis-operations in patients 60 years and older.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification efficacy study
Intervention model parallel assignment
Masking double blind (subject, investigator, outcomes assessor)
Primary purpose treatment
Arm
(Active Comparator)
Allograft used for fusion in the operation site
i-factor i-FACTOR®putty, Cerapedics, USA. CE-brand 0086
i-FACTOR mixed with autologous bone from the decompression placed in the operation site for enhancing fusion
(Experimental)
i-FACTOR used for fusion in the operation site
i-factor i-FACTOR®putty, Cerapedics, USA. CE-brand 0086
i-FACTOR mixed with autologous bone from the decompression placed in the operation site for enhancing fusion

Primary Outcomes

Measure
The clinical effect of i-FACTOR® versus allograft in non-instrumented posterolateral spondylodesis operation in the elderly with spinal stenosis due to degenerative spondylolisthesis measured by ODI
time frame: 24 months postoperative

Secondary Outcomes

Measure
The clinical effect of i-FACTOR® versus allograft in non-instrumented posterolateral spondylodesis operation in the elderly with spinal stenosis due to degenerative spondylolisthesis assessed by fusion rates
time frame: 12 months postoperative

Eligibility Criteria

Male or female participants at least 60 years old.

Inclusion Criteria: - Spinal stenosis, olisthesis grade 1-2 (>3 mm), facet joint arthrosis and flavus hypertrophia verified by a mr-scan and x-ray including maximally 2 levels ranging from L1-S1. - A score of 6 and more on Konno´s "History of Examination Characteristic". - Signed informed content. Exclusion Criteria: - Any disease demanding obligate thromboprophylaxis treatment, including mechanical valve, (DVT with cancer/thrombophilia, AMI, apoplexia cerebri, TCI, valve-operation)< 3 months, coronar metal stent < 6 weeks and coronar drug eluted/coated stent < 12 months. - Atrial fibrillation and one of the following: Mitral stenosis, valveprothesis and apoplexia cerebri/TCI. - Atrial fibrillation and two of the following: Heart insufficient, HT, DM, age > 75 years, EF < 35 %. - Known cancer in the axial skeleton. - Ongoing chemotherapy. - Fracture i the lower back within a year prior to inclusion. - Reduced distance of walking due to non-spinal related causes. - Candidate for more than two-level intervention. - Dementia assessed by the MMSE - ASA 3+4 - Age below 60 years. - Missed 3 months of conservative treatment without success - The use of steroids and bisphosphonates. - Prior radiotherapy to the lower back. - Haematologic disease.

Additional Information

Official title The Clinical Effect of i-FACTOR® Versus Allograft in Non-instrumented Posterolateral Spondylodesis Operation
Principal investigator Michael K Jacobsen, MD
Trial information was received from ClinicalTrials.gov and was last updated in September 2016.
Information provided to ClinicalTrials.gov by Sygehus Lillebaelt.